首页 >> 研究进展
A clinical trial on anti-HBV-DC vaccine combined with thymosin-α1 in the HBeAg negative patients of chronic hepatitis B virus infection
发布时间: 2013-09-02    人气指数:1063

ICI 2013---15th International Congress of Immunology

Poster Presentation (P6.11.76)

Frontiers Immunology (Electronic ISSN:1664-3224), doi: 10.3389/conf.fimmu.2013.02.00896.

Bang-FU Wu1, 2* and Jiang-Ying Yang2

  • 1 Southern Medical University Renkang Hospital, Gastroenterology and Hepatology Center, China
  • 2 Guangzhou Pubang Bio-Immunological Tech Research Institute, China


Aims: To observe the clinical efficacy of anti-HBV-DC vaccine, the dendritic cells originating from peripheral blood mononuclear cells(PBMC) sensitized by HBsAg, in combination with thymosin-α1, in the HBeAg negative patients of chronic hepatitis B virus(HBV) infection.

Methods: 24 inactive HBsAg carriers and 25 chronic hepatitis B(CHB) patients were recruited in the trial. PBMCs obtained from 50ml of heparinized peripheral blood through density gradient centrifuge and adherence method were proliferated under the induction by GM-CSF and IL-4, and sensitized with the 50µg HBsAg. Anti-HBV-DC vaccine was harvested on day 7 and injected, half hypodermically and half intravenously, to the patient once every two weeks for 12 practices applications totally. Thymosin-α1 1.6mg was injected hypodermically twice a week. Quantitative HBVM(TRFIA) and HBVDNA and hepatic functions were evaluated at week 0, 4, 12, and 24.
Results: At week 4, 12 and 24, The HBsAg negative conversion rate were 8.00%(2/25), 12.00(3/25) and 20.00%(5/25) respectively, the HBVDNA negative conversion rate were 63.64%(7/11), 72.73%(8/11) and 72.73%(8/11) in HBeAg negative CHB patients.
The HBsAg negative conversion rate were 12.50%(3/24), 25.00%(6/24) and 37.50%(9/24) respectively in inactive HBsAg carriers.

Conclusions: anti-HBV-DC vaccine in combination with thymosin-α1 can be considered as a safe approach with high efficacy for HBeAg negative patients of chronic HBV infection, which can effectively inhibit the viral replication, decrease rapidly and eliminate the HBsAg, and may eliminate the HBsAg for partial patients.


Keywords: Dendritic Cells (DC), Hepatitis B virus (HBV), Chronic hepatitis B (CHB), Vaccine, Inactive HBsAg carriers

Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.

Presentation Type: Abstract

Topic: Translational immunology and immune intervention

Citation: Wu B and Yang J (2013). A clinical trial on anti-HBV-DC vaccine combined with thymosin-α1 in the HBeAg negative patients of chronic hepatitis B virus infection. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00896

Received: 20 Jun 2013; Published Online: 22 Aug 2013.

* Correspondence: Prof. Bang-FU Wu, Southern Medical University Renkang Hospital, Gastroenterology and Hepatology Center, Dongguan, Guanggong, 523952, China, bangfu.wu@163.com